CN110753545A - 用于前列腺癌的联合疗法 - Google Patents

用于前列腺癌的联合疗法 Download PDF

Info

Publication number
CN110753545A
CN110753545A CN201880039365.1A CN201880039365A CN110753545A CN 110753545 A CN110753545 A CN 110753545A CN 201880039365 A CN201880039365 A CN 201880039365A CN 110753545 A CN110753545 A CN 110753545A
Authority
CN
China
Prior art keywords
day
niraparib
patient
prednisone
abiraterone acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880039365.1A
Other languages
English (en)
Chinese (zh)
Inventor
M.K.于
L.A.斯尼德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62067858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110753545(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to CN202411589875.XA priority Critical patent/CN119235874A/zh
Publication of CN110753545A publication Critical patent/CN110753545A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CN201880039365.1A 2017-04-13 2018-04-09 用于前列腺癌的联合疗法 Pending CN110753545A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411589875.XA CN119235874A (zh) 2017-04-13 2018-04-09 用于前列腺癌的联合疗法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762485164P 2017-04-13 2017-04-13
US62/485164 2017-04-13
PCT/US2018/026661 WO2018191141A1 (en) 2017-04-13 2018-04-09 Combination therapy for prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411589875.XA Division CN119235874A (zh) 2017-04-13 2018-04-09 用于前列腺癌的联合疗法

Publications (1)

Publication Number Publication Date
CN110753545A true CN110753545A (zh) 2020-02-04

Family

ID=62067858

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880039365.1A Pending CN110753545A (zh) 2017-04-13 2018-04-09 用于前列腺癌的联合疗法
CN202411589875.XA Pending CN119235874A (zh) 2017-04-13 2018-04-09 用于前列腺癌的联合疗法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411589875.XA Pending CN119235874A (zh) 2017-04-13 2018-04-09 用于前列腺癌的联合疗法

Country Status (33)

Country Link
US (4) US20180296574A1 (enExample)
EP (3) EP4176878A1 (enExample)
JP (3) JP7141408B2 (enExample)
KR (1) KR20190134718A (enExample)
CN (2) CN110753545A (enExample)
AU (2) AU2018251594A1 (enExample)
CA (1) CA3059562A1 (enExample)
CL (1) CL2019002871A1 (enExample)
CO (1) CO2019011591A2 (enExample)
CR (1) CR20190467A (enExample)
DK (1) DK3609497T3 (enExample)
DO (1) DOP2019000264A (enExample)
EA (1) EA201992430A1 (enExample)
ES (1) ES2931052T3 (enExample)
HR (1) HRP20221327T1 (enExample)
HU (1) HUE060460T2 (enExample)
IL (2) IL269879B2 (enExample)
JO (1) JOP20190244A1 (enExample)
LT (1) LT3609497T (enExample)
MA (1) MA48728B1 (enExample)
MD (1) MD3609497T2 (enExample)
MX (2) MX2019012296A (enExample)
MY (1) MY209010A (enExample)
NI (1) NI201900105A (enExample)
PE (1) PE20200444A1 (enExample)
PH (1) PH12019502317A1 (enExample)
PL (1) PL3609497T3 (enExample)
PT (1) PT3609497T (enExample)
RS (1) RS63832B1 (enExample)
SG (1) SG11201909552VA (enExample)
SM (1) SMT202200467T1 (enExample)
UA (1) UA129514C2 (enExample)
WO (1) WO2018191141A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113546037A (zh) * 2020-04-20 2021-10-26 鲁南制药集团股份有限公司 一种醋酸阿比特龙栓剂及其制备方法
CN114306236A (zh) * 2021-12-15 2022-04-12 湖南慧泽生物医药科技有限公司 用于负载醋酸阿比特龙的自微乳体系及组合物和应用
CN115515584A (zh) * 2020-05-08 2022-12-23 詹森药业有限公司 用醋酸阿比特龙和尼拉帕尼的组合治疗前列腺癌
US11806313B2 (en) 2021-12-15 2023-11-07 Hunan Huize Biopharma S&T Co., Ltd. Abiraterone acetate containing composition and application thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190033599A (ko) 2016-07-29 2019-03-29 얀센 파마슈티카 엔.브이. 전립선암의 치료 방법
WO2020139339A1 (en) * 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer
JP7442328B2 (ja) * 2020-02-03 2024-03-04 株式会社三共 遊技機
CN118973555A (zh) * 2022-04-07 2024-11-15 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
WO2024203348A1 (ja) * 2023-03-31 2024-10-03 ソニーグループ株式会社 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法
WO2025027138A1 (en) * 2023-08-02 2025-02-06 Janssen Pharmaceutica Nv Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528308A (zh) * 2006-08-25 2009-09-09 库伽尔生物科技公司 治疗癌症的方法和组合物
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
EP2336120B1 (en) * 2007-01-10 2014-07-16 MSD Italia S.r.l. Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
WO2009087381A1 (en) 2008-01-08 2009-07-16 Merck Sharp & Dohme Ltd Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2014089324A1 (en) * 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528308A (zh) * 2006-08-25 2009-09-09 库伽尔生物科技公司 治疗癌症的方法和组合物
CN104306977A (zh) * 2006-08-25 2015-01-28 库伽尔生物科技公司 治疗癌症的方法和组合物
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS.GOV: "A Safety and Pharmacokinetics Study of Niraparib Plus Apalutamide in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)", 《HTTPS://CLINICALTRIALS.GOV/CT2/HISTORY/NCT02924766?V_2=VIEW#STUDYPAGETOP》 *
CLINICALTRIALS.GOV: "Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer", 《HTTPS://CLINICALTRIALS.GOV/CT2/HISTORY/NCT01576172?V_52=VIEW#STUDYPAGETOP》 *
CLINICALTRIALS.GOV: "Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects", 《HTTPS://CLINICALTRIALS.GOV/CT2/HISTORY/NCT03012321?V_5=VIEW#STUDYPAGETOP》 *
PHILLIP L. PALMBOS等: "Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise", 《ONCOLOGY》 *
许玉霞等: "阿比特龙联合泼尼松治疗去势抗拒前列腺癌的临床观察", 《肿瘤防治研究》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113546037A (zh) * 2020-04-20 2021-10-26 鲁南制药集团股份有限公司 一种醋酸阿比特龙栓剂及其制备方法
CN113546037B (zh) * 2020-04-20 2024-12-27 鲁南制药集团股份有限公司 一种醋酸阿比特龙栓剂及其制备方法
CN115515584A (zh) * 2020-05-08 2022-12-23 詹森药业有限公司 用醋酸阿比特龙和尼拉帕尼的组合治疗前列腺癌
CN115551506A (zh) * 2020-05-08 2022-12-30 詹森药业有限公司 用醋酸阿比特龙和尼拉帕尼的组合治疗前列腺癌
CN114306236A (zh) * 2021-12-15 2022-04-12 湖南慧泽生物医药科技有限公司 用于负载醋酸阿比特龙的自微乳体系及组合物和应用
CN114306236B (zh) * 2021-12-15 2022-10-21 湖南慧泽生物医药科技有限公司 用于负载醋酸阿比特龙的自微乳体系及组合物和应用
US11806313B2 (en) 2021-12-15 2023-11-07 Hunan Huize Biopharma S&T Co., Ltd. Abiraterone acetate containing composition and application thereof

Also Published As

Publication number Publication date
US20240398837A1 (en) 2024-12-05
UA129514C2 (uk) 2025-05-21
US20240245710A1 (en) 2024-07-25
AU2024202346A1 (en) 2024-05-02
SMT202200467T1 (it) 2023-01-13
SG11201909552VA (en) 2019-11-28
RS63832B1 (sr) 2023-01-31
HRP20221327T1 (hr) 2023-03-17
DOP2019000264A (es) 2020-07-15
IL269879B1 (en) 2025-06-01
MA48728A (fr) 2020-04-08
IL320452A (en) 2025-06-01
CR20190467A (es) 2020-03-09
JP2024023344A (ja) 2024-02-21
EP4176878A1 (en) 2023-05-10
HUE060460T2 (hu) 2023-03-28
MD3609497T2 (ro) 2023-03-31
US20220175801A1 (en) 2022-06-09
PT3609497T (pt) 2023-01-23
JOP20190244A1 (ar) 2019-10-13
PE20200444A1 (es) 2020-02-28
JP2022141881A (ja) 2022-09-29
EP3609497A1 (en) 2020-02-19
MA48728B1 (fr) 2022-10-31
EA201992430A1 (ru) 2020-02-28
ES2931052T3 (es) 2022-12-23
JP2020516646A (ja) 2020-06-11
LT3609497T (lt) 2022-12-12
CL2019002871A1 (es) 2019-12-27
WO2018191141A1 (en) 2018-10-18
MX2019012296A (es) 2019-11-28
EP4176879A1 (en) 2023-05-10
BR112019021466A2 (pt) 2020-05-12
JP7407880B2 (ja) 2024-01-04
PL3609497T3 (pl) 2023-01-23
KR20190134718A (ko) 2019-12-04
IL269879B2 (en) 2025-10-01
MX2023009569A (es) 2023-08-22
CO2019011591A2 (es) 2020-02-28
AU2018251594A1 (en) 2019-10-24
CA3059562A1 (en) 2018-10-18
MY209010A (en) 2025-06-16
NI201900105A (es) 2020-03-11
US20180296574A1 (en) 2018-10-18
JP7141408B2 (ja) 2022-09-22
EP3609497B1 (en) 2022-10-12
DK3609497T3 (da) 2022-10-31
CN119235874A (zh) 2025-01-03
PH12019502317A1 (en) 2020-07-06
IL269879A (enExample) 2019-11-28

Similar Documents

Publication Publication Date Title
JP7407880B2 (ja) 前立腺癌の併用療法
Hoy Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer
TWI533866B (zh) 卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）之新穎抗腫瘤用途
TW202302112A (zh) 索托拉西布給藥方案
EP4340842B1 (en) Sotorasib for use in the treatment of cancer
JP2022518235A (ja) 進行期固形腫瘍がんの治療用ｒｎａ
EP4247363A1 (en) Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
TW202203913A (zh) 使用包含ｇｄｃ—９４４５及ｃｄｋ４／６抑制劑之組合療法治療乳癌
HK40092155A (en) Combination therapy for prostate cancer
EP4301356A1 (en) Treatment of breast cancer with amcenestrant and palbociclib
EA044835B1 (ru) Комбинированная терапия рака предстательной железы
BR112019021466B1 (pt) Composição compreendendo niraparibe, acetato de abiraterona, e prednisona, bem como uso dos referidos compostos
JP2008526773A (ja) ベクロメタゾンジプロピオネート及びプレドニゾンでの、移植片対宿主病及び白血病の治療
US20250268900A1 (en) Combination therapy using a substituted pyrimidin-4(3h)-one and nivolumab as well as its use in the treatment of cancer
Dębska-Szmich et al. Clinical use of cyclin-dependent kinase (CDK) 4/6 inhibitors in patients with breast cancer—literature review
WO2023148345A1 (en) Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
WO2025096262A1 (en) Mdm2 degraders and uses thereof
TW202339748A (zh) 使用經取代之嘧啶-4(3h)-酮之治療方法
CN118632695A (zh) 尼拉帕尼和醋酸阿比特龙加泼尼松用于改善患有转移性去势抵抗性前列腺癌和hrr改变的患者的临床结果

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination